Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Szalay Aladar | 10% Owner | May 15 '24 | Sale | 3.66 | 17,094 | 62,624 | 1,139,821 | May 15 05:59 PM | Szalay Aladar | 10% Owner | May 14 '24 | Sale | 3.58 | 15,426 | 55,274 | 1,156,915 | May 15 05:59 PM | Szalay Aladar | 10% Owner | May 13 '24 | Sale | 3.62 | 3,446 | 12,478 | 1,172,341 | May 15 05:59 PM | Szalay Aladar | 10% Owner | May 08 '24 | Sale | 3.82 | 13,919 | 53,189 | 1,175,787 | May 09 04:38 PM | Szalay Aladar | 10% Owner | May 07 '24 | Sale | 3.67 | 6,025 | 22,111 | 1,189,706 | May 09 04:38 PM | Szalay Aladar | 10% Owner | May 01 '24 | Sale | 3.30 | 33,061 | 109,161 | 1,195,731 | May 01 06:16 PM | Szalay Aladar | 10% Owner | Apr 30 '24 | Sale | 3.12 | 20,535 | 63,981 | 1,228,792 | May 01 06:16 PM | Szalay Aladar | 10% Owner | Apr 29 '24 | Sale | 3.25 | 6,403 | 20,792 | 1,249,327 | May 01 06:16 PM | Szalay Aladar | 10% Owner | Apr 24 '24 | Sale | 3.50 | 8,064 | 28,251 | 1,255,730 | Apr 24 05:50 PM | Szalay Aladar | 10% Owner | Apr 23 '24 | Sale | 3.49 | 22,000 | 76,800 | 1,263,794 | Apr 24 05:50 PM | Szalay Aladar | 10% Owner | Apr 22 '24 | Sale | 3.53 | 14,331 | 50,597 | 1,285,794 | Apr 24 05:50 PM | Szalay Aladar | 10% Owner | Apr 17 '24 | Sale | 3.71 | 22,737 | 84,425 | 1,300,125 | Apr 18 05:00 PM | Szalay Aladar | 10% Owner | Apr 16 '24 | Sale | 3.53 | 48,683 | 171,802 | 1,322,862 | Apr 18 05:00 PM | Yu Yong | VP, Clinical Trial Operations | Dec 15 '23 | Sale | 13.16 | 32,535 | 428,180 | 0 | Dec 18 04:15 PM | Thomas John | Director | Dec 13 '23 | Sale | 13.38 | 9,000 | 120,387 | 463,460 | Dec 14 08:58 PM | Tyree James L | Director | Dec 13 '23 | Sale | 13.22 | 9,000 | 118,969 | 3,460 | Dec 14 08:59 PM | Yu Yong | VP, Clinical Trial Operations | Dec 07 '23 | Sale | 11.85 | 36,800 | 435,995 | 32,535 | Dec 08 05:57 PM | Yu Yong | VP, Clinical Trial Operations | Nov 21 '23 | Sale | 10.26 | 18,665 | 191,555 | 69,335 | Nov 22 04:15 PM | Szalay Aladar | 10% Owner | Oct 25 '23 | Sale | 19.40 | 5,704 | 110,638 | 1,371,545 | Oct 26 05:07 PM | Yu Yong | VP, Clinical Trial Operations | Oct 24 '23 | Option Exercise | 6.00 | 5,200 | 31,200 | 111,335 | Oct 25 04:15 PM | Yu Yong | VP, Clinical Trial Operations | Oct 24 '23 | Sale | 19.11 | 5,200 | 99,351 | 106,135 | Oct 25 04:15 PM | Szalay Aladar | 10% Owner | Oct 23 '23 | Sale | 19.97 | 49,987 | 998,365 | 1,377,249 | Oct 25 04:51 PM | Thomas John | Director | Oct 16 '23 | Sale | 20.71 | 3,333 | 69,038 | 472,460 | Oct 16 06:39 PM | Yu Yong | VP, Clinical Trial Operations | Oct 10 '23 | Option Exercise | 6.00 | 5,200 | 31,200 | 111,335 | Oct 11 04:10 PM | Yu Yong | VP, Clinical Trial Operations | Oct 10 '23 | Sale | 22.01 | 5,200 | 114,462 | 106,135 | Oct 11 04:10 PM | Szalay Aladar | 10% Owner | Oct 05 '23 | Sale | 24.93 | 14,251 | 355,229 | 1,427,236 | Oct 10 04:49 PM | Szalay Aladar | 10% Owner | Oct 03 '23 | Sale | 25.49 | 75,690 | 1,929,225 | 1,441,487 | Oct 04 06:43 PM | Szalay Aladar | 10% Owner | Sep 28 '23 | Sale | 24.12 | 2,289 | 55,211 | 1,517,177 | Sep 29 04:34 PM | Szalay Aladar | 10% Owner | Sep 27 '23 | Sale | 24.47 | 11,257 | 275,459 | 1,519,466 | Sep 29 04:34 PM | Yu Yong | VP, Clinical Trial Operations | Sep 26 '23 | Option Exercise | 6.00 | 5,200 | 31,200 | 111,335 | Sep 27 04:10 PM | Szalay Aladar | 10% Owner | Sep 26 '23 | Sale | 23.79 | 29,805 | 709,177 | 1,530,723 | Sep 27 04:33 PM | Yu Yong | VP, Clinical Trial Operations | Sep 26 '23 | Sale | 23.56 | 5,200 | 122,528 | 106,135 | Sep 27 04:10 PM | Szalay Aladar | 10% Owner | Sep 25 '23 | Sale | 25.77 | 12,458 | 321,004 | 1,560,528 | Sep 27 04:33 PM | Szalay Aladar | 10% Owner | Sep 22 '23 | Sale | 27.33 | 9,042 | 247,123 | 1,572,986 | Sep 25 06:30 PM | Szalay Aladar | 10% Owner | Sep 21 '23 | Sale | 28.46 | 7,549 | 214,878 | 1,582,028 | Sep 25 06:30 PM | Ryder Sean | General Counsel | Sep 20 '23 | Option Exercise | 6.00 | 10,000 | 60,000 | 10,572 | Sep 21 04:30 PM | Yu Yong | VP, Clinical Trial Operations | Sep 20 '23 | Option Exercise | 6.00 | 6,000 | 36,000 | 112,135 | Sep 21 04:35 PM | Ryder Sean | General Counsel | Sep 20 '23 | Sale | 30.00 | 10,000 | 300,000 | 572 | Sep 21 04:30 PM | Yu Yong | VP, Clinical Trial Operations | Sep 20 '23 | Sale | 27.96 | 6,000 | 167,786 | 106,135 | Sep 21 04:35 PM | Szalay Aladar | 10% Owner | Sep 19 '23 | Sale | 26.45 | 32,167 | 850,942 | 0 | Sep 20 04:48 PM | Szalay Aladar | 10% Owner | Sep 18 '23 | Sale | 23.29 | 30,292 | 705,649 | 5,000 | Sep 20 04:48 PM | Thomas John | Director | Sep 18 '23 | Sale | 24.99 | 3,334 | 83,317 | 475,793 | Sep 18 08:12 PM | Yu Yong | VP, Clinical Trial Operations | Sep 15 '23 | Option Exercise | 6.00 | 10,400 | 62,400 | 116,535 | Sep 18 08:13 PM | Yu Yong | VP, Clinical Trial Operations | Sep 15 '23 | Sale | 21.89 | 10,400 | 227,630 | 106,135 | Sep 18 08:13 PM | Thomas John | Director | Sep 15 '23 | Sale | 21.90 | 3,333 | 72,996 | 479,127 | Sep 18 08:12 PM | Szalay Aladar | 10% Owner | Sep 14 '23 | Sale | 22.07 | 25,276 | 557,806 | 35,292 | Sep 15 04:19 PM | Yu Yong | VP, Clinical Trial Operations | Sep 13 '23 | Sale | 21.14 | 29,800 | 629,927 | 106,135 | Sep 15 08:06 PM | Szalay Aladar | 10% Owner | Sep 13 '23 | Sale | 21.44 | 19,032 | 408,093 | 60,568 | Sep 15 04:19 PM | Smither John W | Director | Sep 13 '23 | Sale | 20.78 | 900 | 18,702 | 6,920 | Sep 14 08:18 PM | Szalay Aladar | 10% Owner | Sep 12 '23 | Sale | 22.26 | 20,265 | 451,167 | 79,600 | Sep 13 07:04 PM | Szalay Aladar | 10% Owner | Sep 11 '23 | Sale | 22.22 | 32,351 | 718,702 | 99,865 | Sep 13 07:04 PM | Szalay Aladar | 10% Owner | Sep 08 '23 | Sale | 23.17 | 24,831 | 575,332 | 132,216 | Sep 11 07:05 PM | Szalay Aladar | 10% Owner | Sep 07 '23 | Sale | 24.37 | 12,446 | 303,268 | 157,047 | Sep 11 07:05 PM | Yu Yong | VP, Clinical Trial Operations | Aug 30 '23 | Sale | 24.70 | 19,800 | 489,060 | 135,935 | Aug 30 07:22 PM | Zindrick Thomas | President and CEO | Aug 18 '23 | Sale | 23.73 | 8,349 | 198,122 | 14,651 | Aug 22 04:13 PM | Yu Yong | VP, Clinical Trial Operations | Aug 18 '23 | Sale | 23.73 | 3,265 | 77,478 | 155,735 | Aug 22 04:14 PM | Cappello Joseph | VP, Pharmaceutical Development | Aug 18 '23 | Sale | 23.73 | 3,265 | 77,478 | 5,735 | Aug 22 04:15 PM | Samuelson Doug | Chief Financial Officer | Aug 18 '23 | Sale | 23.73 | 1,297 | 30,778 | 2,303 | Aug 22 04:17 PM | Smalling Ralph | Head of Regulatory | Aug 18 '23 | Sale | 23.73 | 935 | 22,188 | 2,065 | Aug 22 04:18 PM | Jewett Caroline | Head of Quality | Aug 18 '23 | Sale | 23.73 | 515 | 12,221 | 1,135 | Aug 22 04:18 PM | Ryder Sean | General Counsel | Aug 18 '23 | Sale | 23.73 | 328 | 7,783 | 572 | Aug 22 04:16 PM |
|